Submit Your Feeds

Business News • PR NewsWire • Less Glycemic Variability, Better Patient Reported Outcomes with Lantus® and Apidra® Regimen vs. Premix Analog Insulin

Less Glycemic Variability, Better Patient Reported Outcomes with Lantus® and Apidra® Regimen vs. Premix Analog Insulin
Less Glycemic Variability, Better Patient Reported Outcomes with Lantus® and Apidra® Regimen vs. Premix Analog Insulin

PARIS, June 26 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a study which demonstrated that patients using Lantus® (insulin glargine [rDNA origin] injection) once-daily and Apidra® (insulin glulisine [rDNA origin] injection) before meals

View More : http://www.prnewswire.com/news-releases/less-glycemic-variability-better-patient-reported-outcomes-with-lantus-and-apidr...
Releted News by prnewswire
Results From Study of Vascular Calcification in Dialysis Patients Presented in Late-Breaking Clinical Trial Session at ERA-EDTA 2010 Congress
Information-Motivation-Behavioral Skills Analysis Advances Understanding of Barriers to Self-Monitoring of Blood Glucose
Less Glycemic Variability, Better Patient Reported Outcomes with Lantus® and Apidra® Regimen vs. Premix Analog Insulin
Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes
Film Independent Announces Jury Award Winners of 2010 Los Angeles Film Festival, Presented by The Los Angeles Times
Home Sitemap Contact Us
© businessNewsNewsNews.com